ROCKVILLE, Md., Dec. 1, 2020 /PRNewswire/ — Meso Scale Diagnostics, LLC. (MSD) today announced the commercial release of its V-PLEX® Serology Panels for COVID-19. The release includes the V-PLEX SARS-CoV-2 Panel 2, which Operation Warp Speed (OWS) has chosen as the basis of its standard binding assays for immunogenicity assessments in all funded Phase III clinical trials of vaccines.
The serology tests are provided as complete kits, including the same reference standards and controls that will be used in OWS laboratories to analyze clinical trial samples, making it possible for OWS scientists to directly compare quantitative results between different clinical trials. Vaccine developers who use the OWS assays based on the V-PLEX SARS-CoV-2 Panel 2 could leverage correlates of protection established in the early OWS trials, potentially accelerating the development and approval of vaccines worldwide.
Read the full article at: www.prnewswire.com
- About the Author
- Latest Posts
Over the past 11 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.